Trade Biotage - BIOT CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 1.9 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.025632% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.018813% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | SEK | ||||||||
Margin | 20% | ||||||||
Stock exchange | Sweden | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Biotage AB ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 170.2 |
Open* | 168.1 |
1-Year Change* | -13.26% |
Day's Range* | 167.8 - 175.4 |
52 wk Range | 149.80-239.40 |
Average Volume (10 days) | 67.05K |
Average Volume (3 months) | 1.85M |
Market Cap | 11.60B |
P/E Ratio | 48.66 |
Shares Outstanding | 65.98M |
Revenue | 1.52B |
EPS | 3.61 |
Dividend (Yield %) | 0.88168 |
Beta | 1.22 |
Next Earnings Date | Feb 15, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 174.8 | 6.6 | 3.92% | 168.2 | 175.5 | 166.7 |
Feb 2, 2023 | 170.2 | 5.9 | 3.59% | 164.3 | 171.7 | 163.2 |
Feb 1, 2023 | 161.8 | 1.3 | 0.81% | 160.5 | 163.7 | 159.9 |
Jan 31, 2023 | 159.9 | 1.5 | 0.95% | 158.4 | 160.5 | 157.0 |
Jan 30, 2023 | 160.3 | -0.9 | -0.56% | 161.2 | 161.8 | 157.5 |
Jan 27, 2023 | 161.8 | 2.7 | 1.70% | 159.1 | 162.3 | 159.1 |
Jan 26, 2023 | 160.5 | 3.7 | 2.36% | 156.8 | 162.0 | 156.8 |
Jan 25, 2023 | 158.5 | 1.8 | 1.15% | 156.7 | 158.5 | 154.8 |
Jan 24, 2023 | 157.3 | 1.1 | 0.70% | 156.2 | 162.7 | 155.5 |
Jan 23, 2023 | 156.2 | 1.8 | 1.17% | 154.4 | 157.9 | 153.9 |
Jan 20, 2023 | 152.2 | 1.0 | 0.66% | 151.2 | 153.7 | 147.6 |
Jan 19, 2023 | 152.7 | -2.8 | -1.80% | 155.5 | 157.6 | 150.9 |
Jan 18, 2023 | 156.8 | -7.5 | -4.56% | 164.3 | 165.4 | 152.6 |
Jan 17, 2023 | 172.4 | 1.9 | 1.11% | 170.5 | 172.9 | 168.5 |
Jan 16, 2023 | 173.8 | -1.9 | -1.08% | 175.7 | 176.1 | 170.0 |
Jan 13, 2023 | 175.1 | -1.8 | -1.02% | 176.9 | 177.2 | 171.3 |
Jan 12, 2023 | 170.5 | -3.5 | -2.01% | 174.0 | 175.5 | 169.2 |
Jan 11, 2023 | 174.0 | 0.5 | 0.29% | 173.5 | 177.2 | 172.4 |
Jan 10, 2023 | 173.5 | 0.7 | 0.41% | 172.8 | 175.6 | 171.4 |
Jan 9, 2023 | 173.9 | -0.6 | -0.34% | 174.5 | 177.1 | 172.1 |
Biotage Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 667.912 | 748.147 | 910.896 | 1101.37 | 1092.28 | 1232 |
Revenue | 667.912 | 748.147 | 910.896 | 1101.37 | 1092.28 | 1232 |
Cost of Revenue, Total | 282.098 | 291.483 | 354.27 | 415.963 | 425.55 | 477 |
Gross Profit | 385.814 | 456.664 | 556.626 | 685.41 | 666.728 | 755 |
Total Operating Expense | 568.798 | 614.517 | 738.418 | 893.253 | 886.093 | 961 |
Selling/General/Admin. Expenses, Total | 237.338 | 254.497 | 313.127 | 360.028 | 336.94 | 374 |
Research & Development | 17.326 | 33.581 | 43.101 | 49.733 | 44.102 | 56 |
Depreciation / Amortization | 39.795 | 30.241 | 34.032 | 65.132 | 66.449 | 65 |
Interest Expense (Income) - Net Operating | -7.004 | -8.309 | -14.681 | -2.41 | -19.352 | -16 |
Unusual Expense (Income) | 0 | 2.5 | 2.5 | |||
Other Operating Expenses, Total | -0.755 | 13.024 | 6.069 | 2.307 | 32.404 | 5 |
Operating Income | 99.114 | 133.63 | 172.478 | 208.12 | 206.185 | 271 |
Interest Income (Expense), Net Non-Operating | -6.713 | 2.63 | 3.811 | 3.949 | -8.901 | -12 |
Other, Net | 0 | 0 | 0 | -0.077 | 25.445 | 10 |
Net Income Before Taxes | 92.401 | 136.26 | 176.289 | 211.992 | 222.729 | 269 |
Net Income After Taxes | 92.795 | 138.747 | 167.627 | 186.82 | 175.331 | 205 |
Net Income Before Extra. Items | 92.795 | 138.747 | 167.627 | 186.82 | 175.331 | 205 |
Net Income | 92.795 | 138.747 | 167.627 | 186.82 | 175.331 | 205 |
Total Adjustments to Net Income | 0.001 | |||||
Income Available to Common Excl. Extra. Items | 92.796 | 138.747 | 167.627 | 186.82 | 175.331 | 205 |
Income Available to Common Incl. Extra. Items | 92.796 | 138.747 | 167.627 | 186.82 | 175.331 | 205 |
Diluted Net Income | 92.796 | 138.747 | 167.627 | 186.82 | 175.331 | 205 |
Diluted Weighted Average Shares | 64.7144 | 64.7144 | 64.7144 | 65.1821 | 65.2085 | 65.4648 |
Diluted EPS Excluding Extraordinary Items | 1.43393 | 2.14399 | 2.59026 | 2.86612 | 2.68877 | 3.13145 |
Dividends per Share - Common Stock Primary Issue | 1.25 | 1.4 | 1.5 | 0 | 1.5 | 1.55 |
Diluted Normalized EPS | 1.43393 | 2.14399 | 2.62699 | 2.89992 | 2.68877 | 3.17802 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 281.35 | 303.458 | 305 | 342 | 386 |
Revenue | 281.35 | 303.458 | 305 | 342 | 386 |
Cost of Revenue, Total | 103.889 | 121.281 | 122 | 130 | 145 |
Gross Profit | 177.461 | 182.177 | 183 | 212 | 241 |
Total Operating Expense | 201.972 | 240.943 | 237 | 281 | 290 |
Selling/General/Admin. Expenses, Total | 86.447 | 94.618 | 100 | 123 | 122 |
Research & Development | 19.389 | 23.065 | 19 | 29 | 25 |
Other Operating Expenses, Total | -7.753 | 1.979 | -4 | -1 | -2 |
Operating Income | 79.378 | 62.515 | 68 | 61 | 96 |
Interest Income (Expense), Net Non-Operating | -2.166 | -1.94 | -2 | 4 | -4 |
Net Income Before Taxes | 77.212 | 60.575 | 66 | 65 | 92 |
Net Income After Taxes | 60.039 | 45.973 | 53 | 46 | 71 |
Net Income Before Extra. Items | 60.039 | 45.973 | 53 | 46 | 71 |
Net Income | 60.039 | 45.973 | 53 | 46 | 71 |
Total Adjustments to Net Income | 0.001 | ||||
Income Available to Common Excl. Extra. Items | 60.04 | 45.973 | 53 | 46 | 71 |
Income Available to Common Incl. Extra. Items | 60.04 | 45.973 | 53 | 46 | 71 |
Diluted Net Income | 60.04 | 45.973 | 53 | 46 | 71 |
Diluted Weighted Average Shares | 65.2304 | 65.2674 | 65.3455 | 66.016 | 65.9838 |
Diluted EPS Excluding Extraordinary Items | 0.92043 | 0.70438 | 0.81107 | 0.6968 | 1.07602 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 1.55 | 0 |
Diluted Normalized EPS | 0.92043 | 0.72531 | 0.81353 | 0.70752 | 1.07602 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 355.98 | 409.252 | 494.438 | 586.569 | 751.615 | 774 |
Cash and Short Term Investments | 128.622 | 174.263 | 177.02 | 185.867 | 371.325 | 311 |
Cash & Equivalents | 128.622 | 174.263 | 177.02 | 185.867 | 371.325 | 311 |
Total Receivables, Net | 130.89 | 128.939 | 173.728 | 212.815 | 207.455 | 207 |
Accounts Receivable - Trade, Net | 118.348 | 118.191 | 156.042 | 197.651 | 194.018 | 180 |
Total Inventory | 88.906 | 95.794 | 132.338 | 173.76 | 159.823 | 237 |
Prepaid Expenses | 7.561 | 10.256 | 11.352 | 14.128 | 13.013 | 19 |
Other Current Assets, Total | 0.001 | -0.001 | -0.001 | |||
Total Assets | 695.196 | 757.201 | 1003.2 | 1335.69 | 1434.44 | 1992 |
Property/Plant/Equipment, Total - Net | 45.447 | 45.303 | 48.63 | 112.253 | 103.656 | 128 |
Property/Plant/Equipment, Total - Gross | 120.207 | 128.483 | 130.51 | 215.717 | 201.79 | 324 |
Accumulated Depreciation, Total | -74.76 | -83.18 | -81.88 | -103.464 | -98.134 | -196 |
Goodwill, Net | 104.023 | 104.023 | 186.055 | 315.869 | 290.209 | 741 |
Intangibles, Net | 116.015 | 118.646 | 192.654 | 260.047 | 250.787 | 313 |
Long Term Investments | 18.645 | 17.838 | 17.368 | 16.614 | 12.254 | 14 |
Note Receivable - Long Term | 1.156 | 0 | 0.003 | |||
Other Long Term Assets, Total | 53.93 | 62.139 | 64.055 | 44.335 | 25.92 | 22 |
Total Current Liabilities | 127.721 | 144.377 | 173.397 | 212.272 | 217.364 | 313 |
Accounts Payable | 38.133 | 47.457 | 54.764 | 41.461 | 51.236 | 56 |
Payable/Accrued | -0.001 | 0.001 | ||||
Accrued Expenses | 47.103 | 50.561 | 60.411 | 69.334 | 58.479 | |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 21.231 | 21.214 | 23 | ||
Other Current Liabilities, Total | 42.486 | 46.359 | 58.222 | 80.245 | 86.435 | 234 |
Total Liabilities | 131.958 | 148.59 | 301.023 | 460.184 | 444.403 | 621 |
Total Long Term Debt | 0 | 0 | 109.4 | 147.647 | 140.677 | 180 |
Deferred Income Tax | 1.759 | 1.621 | 14.78 | 28.884 | 32.838 | 73 |
Other Liabilities, Total | 2.478 | 2.592 | 3.446 | 71.381 | 53.524 | 55 |
Total Equity | 563.238 | 608.611 | 702.18 | 875.503 | 990.038 | 1371 |
Common Stock | 89.953 | 89.953 | 89.953 | 90.63 | 90.969 | 92 |
Retained Earnings (Accumulated Deficit) | 557.223 | 615.077 | 692.104 | 781.121 | 956.114 | 1063 |
Other Equity, Total | -83.938 | -96.419 | -79.877 | 3.752 | -116.547 | -50 |
Total Liabilities & Shareholders’ Equity | 695.196 | 757.201 | 1003.2 | 1335.69 | 1434.44 | 1992 |
Total Common Shares Outstanding | 64.7144 | 64.7144 | 64.7144 | 64.7144 | 65.2018 | 65.9838 |
Long Term Debt | 109.4 | 109.55 | 110 | 150 | ||
Capital Lease Obligations | 38.097 | 30.677 | 30 | |||
Additional Paid-In Capital | 59.502 | 266 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 851.273 | 694.254 | 784 | 774 | 842 |
Cash and Short Term Investments | 422.068 | 278.552 | 359 | 311 | 349 |
Cash & Equivalents | 422.068 | 278.552 | 359 | 311 | 349 |
Total Receivables, Net | 237.214 | 221.377 | 217 | 226 | 249 |
Accounts Receivable - Trade, Net | 204.607 | 191.724 | 181 | 226 | 216 |
Total Inventory | 191.992 | 194.326 | 208 | 237 | 244 |
Other Current Assets, Total | -0.001 | -0.001 | |||
Total Assets | 1575.81 | 1409.61 | 1503 | 1992 | 2056 |
Property/Plant/Equipment, Total - Net | 126.05 | 125.751 | 124 | 128 | 126 |
Goodwill, Net | 302.381 | 297.524 | 304 | 741 | 746 |
Intangibles, Net | 259.79 | 257.747 | 257 | 313 | 309 |
Long Term Investments | 12.263 | 12.224 | 12 | 14 | 15 |
Other Long Term Assets, Total | 24.051 | 22.115 | 22 | 22 | 18 |
Total Current Liabilities | 246.435 | 263.719 | 289 | 313 | 298 |
Accounts Payable | 53.503 | 46.03 | 54 | 56 | 43 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 22.653 | 23.289 | 24 | 23 | 23 |
Other Current Liabilities, Total | 170.279 | 194.4 | 211 | 234 | 232 |
Total Liabilities | 493.496 | 390.115 | 413 | 621 | 601 |
Total Long Term Debt | 153.626 | 40.861 | 37 | 180 | 175 |
Long Term Debt | 110 | 0 | 0 | 150 | 150 |
Capital Lease Obligations | 43.626 | 40.861 | 37 | 30 | 25 |
Deferred Income Tax | 36.325 | 36.86 | 37 | 73 | 72 |
Other Liabilities, Total | 57.11 | 48.675 | 50 | 55 | 56 |
Total Equity | 1082.31 | 1019.5 | 1090 | 1371 | 1455 |
Common Stock | 90.969 | 90.969 | 91 | 92 | 92 |
Additional Paid-In Capital | 60.137 | 61.239 | 64 | 266 | 269 |
Retained Earnings (Accumulated Deficit) | 1016.15 | 964.324 | 1017 | 1063 | 1134 |
Other Equity, Total | -84.948 | -97.032 | -82 | -50 | -40 |
Total Liabilities & Shareholders’ Equity | 1575.81 | 1409.61 | 1503 | 1992 | 2056 |
Total Common Shares Outstanding | 65.2018 | 65.2018 | 65.2018 | 65.9838 | 65.9838 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | 92.401 | 136.26 | 176.289 | 211.992 | 222.729 | 269 |
Cash From Operating Activities | 139.072 | 168.932 | 155.005 | 211.807 | 279.047 | 353 |
Cash From Operating Activities | 43.836 | 34.225 | 39.412 | 74.372 | 73.904 | 75 |
Non-Cash Items | -1.187 | 1.991 | -11.727 | 2.129 | -11.661 | 4 |
Cash Taxes Paid | 5.363 | 5.091 | 9.314 | 9.925 | 15.083 | 16 |
Cash Interest Paid | 0.023 | 0.002 | 1.738 | 2.86 | 3.339 | 3 |
Changes in Working Capital | 4.022 | -3.544 | -48.969 | -76.686 | -5.925 | 5 |
Cash From Investing Activities | -67.726 | -36.903 | -178.411 | -85.676 | -61.32 | -341 |
Capital Expenditures | -47.54 | -37.804 | -47.158 | -45.454 | -60.941 | -56 |
Other Investing Cash Flow Items, Total | -20.186 | 0.901 | -131.253 | -40.222 | -0.379 | -285 |
Cash From Financing Activities | -81.152 | -81.053 | 19.342 | -119.205 | -22.723 | -82 |
Total Cash Dividends Paid | -80.893 | -80.893 | -90.6 | -97.803 | 0 | -98 |
Issuance (Retirement) of Debt, Net | -0.259 | -0.16 | 109.942 | -21.402 | -22.723 | 16 |
Foreign Exchange Effects | 3.544 | -5.336 | 6.821 | 1.921 | -9.547 | 9 |
Net Change in Cash | -6.262 | 45.64 | 2.757 | 8.847 | 185.457 | -61 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 77.212 | 137.787 | 204 | 269 | 92 |
Cash From Operating Activities | 67.62 | 159.904 | 249 | 353 | 57 |
Cash From Operating Activities | 17.133 | 35.656 | 54 | 75 | 23 |
Non-Cash Items | -1.912 | -2.579 | -5 | 4 | 5 |
Cash Taxes Paid | 4.569 | 8.686 | 14 | 16 | 15 |
Changes in Working Capital | -24.813 | -10.96 | -4 | 5 | -63 |
Cash From Investing Activities | -18.266 | -34.637 | -45 | -341 | -14 |
Capital Expenditures | -18.266 | -34.137 | -44 | -56 | -14 |
Other Investing Cash Flow Items, Total | 0 | -0.5 | -1 | -285 | 0 |
Cash From Financing Activities | -5.17 | -223.759 | -227 | -82 | -6 |
Issuance (Retirement) of Debt, Net | -5.17 | -125.956 | -129 | 16 | -6 |
Foreign Exchange Effects | 6.559 | 5.719 | 10 | 9 | 2 |
Net Change in Cash | 50.743 | -92.773 | -13 | -61 | 39 |
Total Cash Dividends Paid | -97.803 | -98 | -98 | 0 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
SEB Investment Management AB | Investment Advisor | 7.55 | 4981775 | -6598 | 2022-12-31 | LOW |
Swedbank Robur Fonder AB | Investment Advisor/Hedge Fund | 6.84 | 4513290 | -1505315 | 2022-12-31 | LOW |
Invesco Advisers, Inc. | Investment Advisor | 5.75 | 3794067 | -41121 | 2022-12-31 | LOW |
ODIN Forvaltning AS | Investment Advisor | 4.5 | 2969270 | -30730 | 2022-12-31 | LOW |
Didner & Gerge Fonder AB | Investment Advisor | 3.75 | 2474392 | 1493504 | 2022-12-31 | LOW |
Handelsbanken Kapitalförvaltning AB | Investment Advisor/Hedge Fund | 3.56 | 2349022 | -131968 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.39 | 2236850 | 52787 | 2022-12-31 | LOW |
Lannebo Fonder AB | Investment Advisor/Hedge Fund | 3.24 | 2137874 | -26564 | 2022-12-31 | LOW |
Tredje AP Fonden | Pension Fund | 3.1 | 2045497 | 310124 | 2022-12-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.31 | 1524225 | -6599 | 2022-12-31 | LOW |
Första AP-Fonden | Pension Fund | 1.99 | 1313077 | -257337 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.86 | 1227298 | 59385 | 2022-12-31 | LOW |
TIN Fonder | Investment Advisor | 1.53 | 1009552 | -10412 | 2022-12-31 | MED |
Montanaro Asset Management Limited | Investment Advisor | 1.37 | 903978 | 219232 | 2022-12-31 | LOW |
M & G Investment Management Ltd. | Investment Advisor | 1.25 | 824797 | 0 | 2022-12-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.14 | 752215 | -39590 | 2022-09-30 | LOW |
Goldman Sachs Asset Management, L.P. | Investment Advisor | 1.0636 | 701784 | -154 | 2022-11-30 | LOW |
DNCA Investments | Investment Advisor | 0.9396 | 620000 | -50224 | 2022-12-31 | LOW |
Danske Bank Asset Management | Investment Advisor | 0.9353 | 617175 | 15262 | 2022-12-31 | LOW |
Nordea Funds Oy | Investment Advisor | 0.8444 | 557198 | -45107 | 2022-12-31 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com GroupTraders
Active clients monthly
Monthly investing volume
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Biotage Company profile
Biotage is a Sweden-based Life Science company, specialising in separation and synthesis solutions. The company’s offering comprises three distinct product lines. The Organic Chemistry line seeks to rationalise the development of drugs by purifying substances that will become new drugs. The Analytical Chemistry line aims to reinvent the sample analysis. The Industrial Product line offers innovative systems and consumables that separate substances during the large-scale production. All product lines are available across Europe and the US by the Biotage sales organisation or by distributors. Headquartered in Uppsala, Sweden, Biotage trades on the NASDAQ Stockholm under the BIOT ticker. Find out the latest BIOT stock news at Capital.com.Industry: | Medical Diagnostic & Testing Equipment |
Vimpelgatan 5
UPPSALA
UPPSALA 753 18
SE
Income Statement
- Annual
- Quarterly
News

S&P 500 & DAX 40 Forecast for the Week Ahead
S&P 500 builds higher after Fed meeting, DAX 40 runs into resistance
16:30, 3 February 2023
FX Weekly Outlook: USD, GBP/USD, USD/JPY Analysis
USD, GBP/USD, USD/JPY forecasts for the week ahead.
15:56, 3 February 2023
GBP/USD drops below 1.23 as BOE comments suggest possible end of rate hikes
Despite increasing rates by 50bps at their February meeting, the messaging from the BOE suggests a dovish tilt an the possible end of rate hikes.
15:37, 2 February 2023
Gold latest: XAU/USD rallies on Fed meeting as traders eye Friday’s jobs data
Gold buyers take advantage of risk on sentiment as they eye Friday's NFP data to assess the likelihood of a soft landing
11:48, 2 February 2023
British Pound (GBP) Outlook: GBP/USD, EUR/GBP Ahead of BoE Rate Decision
Bank of England remains a dovish hiker. GBP at risk of another dovish twist
15:13, 1 February 2023People also watch
Still looking for a broker you can trust?
Join the 480.000+ traders worldwide that chose to trade with Capital.com